BackEuropean Biotech Acquisition Overview

European Biotech Acquisition Current Cash

Track European Biotech Acquisition's current cash ($310K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$308488.00
↓ 64.47% YoYΔ $-559792.00 vs prior year quarter

Peer average

Loading

European Biotech Acquisition Current Cash History

Loading

European Biotech Acquisition vs. peers: Current Cash Comparison

Loading

European Biotech Acquisition Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

European Biotech Acquisition (EBAC) FAQ

The latest current cash for EBAC is $310K as of December 2022. That compares with $870K in the prior-year period — down 64.5% year over year. Investors often review this figure alongside European Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBAC's current cash moved from $870K to $310K — a 64.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition's operating scale or balance-sheet position.

A current cash figure of $310K for EBAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBAC's current cash ($310K), review year-over-year change from $870K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.